Risk of suicide-related deaths (SRD) among patients diagnosed with metastatic genitourinary (mGU) cancers: A retrospective cohort study.

Authors

Ahsan Ayaz

Ahsan Ayaz

Montefiore St. Luke's Cornwall Hospital, Newburgh, NY

Ahsan Ayaz , Syed Arsalan Ahmed Naqvi , Manal Imran , Akshat Saxena , Ammad Raina , Kaneez Zahra Rubab Khakwani , Ewan Kemar Cobran , Sajid Ahmad Mir , Parminder Singh , Alan Haruo Bryce , Irbaz Bin Riaz

Organizations

Montefiore St. Luke's Cornwall Hospital, Newburgh, NY, Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, Dow Medical College, Karachi, Pakistan, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Canyon Vista Medical Center, Sierra Vista, AZ, University of Arizona, Tucson, AZ, Mayo Clinic College of Medicine and Science, Scottsdale, AZ, Montefiore St. Luke's Cornwall Program, Newburgh, NY, Mayo Clinic, Phoenix, AZ, Mayo Clinic Arizona, Scottsdale, AZ, Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ

Research Funding

No funding sources reported

Background: Elevated suicide risk is established in cancer patients compared with the general population. We aim to investigate the risk of SRD among individuals diagnosed with mGU cancers. Methods: Surveillance, Epidemiology, and End Results (SEER) database (2004-2020) was queried to obtain data on suicide death in adults (>20 years of age) diagnosed with mGU cancers including bladder cancer (BC), kidney cancer (KC), and prostate cancer (PC). Standardized mortality ratios (SMRs) with 95% confidence interval (CI) were computed overall and by latency period of <1, 1-5, and >5 years (y) after the initial diagnosis of mGU cancers. SMR >1 indicated increased while <1 indicated decreased SRD. Stratification was done by age (<50y, 50-70y, >70y), race (White, Black, Asian, Native American), ethnicity (Hispanic, non-Hispanic), chemotherapy, radiotherapy, surgery, and marital. Results: This analysis included 87,357 mGU patients. In overall population, the risk of suicide-related deaths was highest <1y after diagnosis (SMR: 3.29, 95% CI: 2.47-4.29) followed by 1-5y (2.61, 2.0-3.35) and >5y (1.27, 0.61-2.34) after diagnosis. With respect to race, SRD was significantly higher in Whites (3.31, 2.46-4.36) but not in Blacks (2.58, 0.31-9.33), and Asians (2.03 (0.05-11.3). In ethnic subgroups, non-Hispanics were observed to have increased SRD (3.71, 2.77-4.86) but not Hispanics (0.83, 0.1-3.0). Patients who received chemotherapy (3.74, 2.10-6.18) or those who did not receive radiotherapy (3.66, 2.68-4.89) were more likely to die from suicide. In terms of marital status, single patients had a higher SRD (4.39, 2.94-6.30) compared to those who were married (2.54, 1.65-3.76). Detailed results are outlined in the Table. Conclusions: Patients with GU malignancies are at increased risk of SRD. Targeted and timely interventions in highest risk subgroups such as Non-Hispanic patients with a recent cancer diagnosis with no partner support, may reduce the risk of SRD in patients diagnosed with mGU cancers.

SubgroupAll GU CancersBCKCPC
SMR (95 % CI)
Overall Population3.29 (2.47-4.29)5.98 (2.41-12.33)5.99 (3.71-9.16)2.21 (1.44-3.24)
Age 50-70 years3.51 (2.25-5.22)7.58 (2.07-19.41)5.95 (3.08-10.4)1.86 (0.80-3.67)
Age >70 years3.38 (2.28-4.82)5.27 (1.09-15.40)8.43 (3.85-16.0)2.48 (1.47-3.92)
White3.31 (2.46-4.36)6.32 (2.54-13.02)5.50 (3.26-8.68)2.33 (1.51-3.44)
Non-Hispanic3.71 (2.77-4.86)6.67 (2.68-13.73)6.60 (3.97-10.3)2.58 (1.68-3.77)
Chemotherapy - Yes3.74 (2.10-6.18)2.67 (0.32-9.65)6.13 (3.06-10.96)1.37 (0.17-4.94)
Radiotherapy - No3.66 (2.68-4.89)6.53 (2.40-14.21)7.57 (4.56-11.82)2.30 (1.42-3.52)
Surgery - Yes2.28 (1.04-4.33)3.15 (0.65-9.21)2.93 (0.95-6.85)0.78 (0.02-4.32)
Married2.54 (1.65-3.76)2.95 (0.36-10.67)4.92 (2.46-8.81)1.74 (0.90-3.03)
Single4.39 (2.94-6.30)10.14 (3.29-23.66)7.86 (3.77-14.46)2.89 (1.58-4.85)

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Other

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 230)

DOI

10.1200/JCO.2024.42.4_suppl.230

Abstract #

230

Poster Bd #

K18

Abstract Disclosures

Similar Abstracts

First Author: Ahsan Ayaz

First Author: Prantik Das

First Author: Yicong Chen

First Author: Edward Christopher Dee